Sudeep Pharma Limited

As of June 30, 2026, Sudeep Pharma Limited carries a market capitalization of 95.09B, placing it among publicly traded companies globally. Its enterprise value stands at 95.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sudeep Pharma Limited's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Sudeep Pharma Limited has 112.95M shares outstanding.

As of June 30, 2026, Sudeep Pharma Limited trades at a trailing price-to-earnings ratio of 56.41.

As of June 30, 2026, Sudeep Pharma Limited trades at an EV/EBITDA multiple of 42.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 46.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 95.09B versus a market cap of 95.09B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 11.28M in revenue per employee across its workforce of 565.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sudeep Pharma Limited recorded 547.40M in income tax expense. That works out to an effective tax rate of 24.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.23B, leaving 1.68B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 23, 2026. The 50-day moving average sits at 1,139.38, while the 200-day moving average is 810.68.

Over the twelve months ended June 30, 2026, Sudeep Pharma Limited generated 6.38B in revenue and converted that into 1.68B in net income, yielding earnings per share of 14.96. EBITDA reached 2.21B, while operating income came in at 2.06B.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sudeep Pharma Limited posted a gross margin of 65.05, reflecting its pricing power and cost economics. The operating margin of 32.35 and net profit margin of 26.29 provide insight into operational efficiency.